$128.29
3.22% yesterday
Nasdaq, Nov 15, 09:46 pm CET
ISIN
US04351P1012
Symbol
ASND
Sector
Industry

Ascendis Pharma A/S Sponsored ADR Target price 2024 - Analyst rating & recommendation

Ascendis Pharma A/S Sponsored ADR Classifications & Recommendation:

Buy
93%
Hold
7%

Ascendis Pharma A/S Sponsored ADR Price Target

Target Price $192.49
Price $126.51
Potential
Number of Estimates 15
15 Analysts have issued a price target Ascendis Pharma A/S Sponsored ADR 2025 . The average Ascendis Pharma A/S Sponsored ADR target price is $192.49. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 15 analysts: 14 Analysts recommend Ascendis Pharma A/S Sponsored ADR to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Ascendis Pharma A/S Sponsored ADR stock has an average upside potential 2025 of . Most analysts recommend the Ascendis Pharma A/S Sponsored ADR stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 288.35 318.45
436.17% 10.44%
EBITDA Margin -163.71% -98.62%
84.60% 39.76%
Net Margin -183.97% -135.19%
84.22% 26.52%

14 Analysts have issued a sales forecast Ascendis Pharma A/S Sponsored ADR 2024 . The average Ascendis Pharma A/S Sponsored ADR sales estimate is

$318m
Unlock
. This is
7.20% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$432m 25.95%
Unlock
, the lowest is
$275m 19.81%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $288m 436.17%
2024
$318m 10.44%
Unlock
2025
$572m 79.65%
Unlock
2026
$1.1b 83.54%
Unlock
2027
$1.8b 73.85%
Unlock
2028
$2.5b 34.94%
Unlock

6 Analysts have issued an Ascendis Pharma A/S Sponsored ADR EBITDA forecast 2024. The average Ascendis Pharma A/S Sponsored ADR EBITDA estimate is

$-314m
Unlock
. This is
13.31% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-218m 39.79%
Unlock
, the lowest is
$-376m 3.77%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-472m 17.41%
2024
$-314m 33.47%
Unlock
2025
$-128m 59.17%
Unlock
2026
$251m 295.91%
Unlock
2027
$1.5b 507.47%
Unlock
2028
$2.4b 56.42%
Unlock

EBITDA Margin

2023 -163.71% 84.60%
2024
-98.62% 39.76%
Unlock
2025
-22.42% 77.27%
Unlock
2026
23.93% 206.74%
Unlock
2027
83.60% 249.35%
Unlock
2028
96.91% 15.92%
Unlock

6 Ascendis Pharma A/S Sponsored ADR Analysts have issued a net profit forecast 2024. The average Ascendis Pharma A/S Sponsored ADR net profit estimate is

$-431m
Unlock
. This is
19.63% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-379m 29.30%
Unlock
, the lowest is
$-456m 14.87%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-530m 15.37%
2024
$-431m 18.84%
Unlock
2025
$-240m 44.33%
Unlock
2026
$-2.9m 98.81%
Unlock
2027
$261m 9,265.26%
Unlock
2028
$579m 121.50%
Unlock

Net Margin

2023 -183.97% 84.22%
2024
-135.19% 26.52%
Unlock
2025
-41.89% 69.01%
Unlock
2026
-0.27% 99.36%
Unlock
2027
14.31% 5,400.00%
Unlock
2028
23.49% 64.15%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -9.25 -7.51
15.37% 18.81%
P/E negative
EV/Sales 24.18

6 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast for earnings per share. The average Ascendis Pharma A/S Sponsored ADR <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-7.51
Unlock
. This is
19.59% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-6.60 29.34%
Unlock
, the lowest is
$-7.95 14.88%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-9.25 15.37%
2024
$-7.51 18.81%
Unlock
2025
$-4.18 44.34%
Unlock
2026
$-0.05 98.80%
Unlock
2027
$4.55 9,200.00%
Unlock
2028
$10.09 121.76%
Unlock

P/E ratio

Current -13.55 70.87%
2024
-16.85 24.35%
Unlock
2025
-30.27 79.64%
Unlock
2026
-2,544.07 8,304.59%
Unlock
2027
27.78 101.09%
Unlock
2028
12.54 54.86%
Unlock

Based on analysts' sales estimates for 2024, the Ascendis Pharma A/S Sponsored ADR stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

24.18
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
22.78
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 22.43 31.28%
2024
24.18 7.79%
Unlock
2025
13.46 44.34%
Unlock
2026
7.33 45.52%
Unlock
2027
4.22 42.48%
Unlock
2028
3.13 25.89%
Unlock

P/S ratio

Current 21.14 32.40%
2024
22.78 7.76%
Unlock
2025
12.68 44.34%
Unlock
2026
6.91 45.52%
Unlock
2027
3.97 42.48%
Unlock
2028
2.95 25.89%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today